Analyst Brandon Folkes of H.C. Wainwright reiterated a Buy rating on MannKind, retaining the price target of $11.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Brandon Folkes has given his Buy rating due to a combination of factors that highlight MannKind’s strong financial performance and promising growth prospects. The company reported impressive third-quarter results for 2025, surpassing both the firm’s and consensus expectations in terms of revenue and earnings per share. The acquisition of ScPharma assets is expected to contribute to long-term growth, and MannKind’s pipeline developments, including the FDA’s acceptance of the Afrezza pediatric application, indicate potential for further expansion.
Additionally, MannKind’s Afrezza sales showed a significant year-over-year increase, driven by higher demand and prescription growth. The company’s ongoing clinical trials and regulatory submissions, such as the global Phase 3 ICoN-1 study and the sNDA for the FUROSCIX ReadyFlow Autoinjector, further support the positive outlook. The valuation model, incorporating a discounted cash flow analysis, reflects these optimistic projections, leading to a 12-month price target of $11. Despite potential risks, such as commercial execution and regulatory challenges, the overall assessment suggests a favorable investment opportunity in MannKind’s stock.
In another report released on October 30, Wedbush also maintained a Buy rating on the stock with a $11.00 price target.